Secretion of metastasis related gangliosides by mouse B16-melanoma in circulation <i>in vivo </i>and in culture media <i>in vitro</i>

Abstract

Mouse B l6LuFI melanoma cells of lower metastatic potential to lung were treated <i>in</i> <i>vitro </i>with same concentration (50<i>μM</i>)<i> </i>of gangliosides prepared from plasma of mice bearing lung metastasis of B16LuF5, B16LuF9 or B16LuF10 melanoma cell lines of increasing metastatic potential to lung(LuF1< LuF5 < LuF9< LuF10) and injected to normal mice through tail vein. The number of metastatic tumor nodules formed in lung increased gradually in mice receiving B16LuF5, B16LuF9 and B16LuF10-ganglioside-treated B16LuF1 cells compared to mice receiving B16LuF1 cells without any ganglioside treatment. Similarly, mouse B16LuF1 melanoma cells treated <i>in</i> <i>vitro </i>with 50<i>μM </i>concentration of gangliosides prepared from spent culture media of Bl6LuF5, B16LuF9 or B16LuF10 cells cultured <i>in</i> <i>vitro </i>were injected to normal mice through tail vein. The number of metastatic tumor nodules formed in lung increased gradually in mice receiving B16LuF5, B16LuF9 and B16LuF10-ganglioside-treated B16LuF1 cells compared to mice receiving B16LuF1 cells without any ganglioside treatment. The results indicated that metastasis-associated gangliosides present in plasma and culture media of B16-melanoma of increasing metastatic potential to lung enhanced metastatic potential of B16LuF1 cells. The increasing concentration of metastasis-associated gangliosides present in plasma and in culture media of B16-melanoma of increasing metastatic potential possibly determined increase in metastatic potential of B16LuF1-melanoma cells.